RxDoctor Payments Data

Hameed Khan, MD

Family Medicine · Torrance, CANPI 1710986740

Payments from drug & device makers

$8,572in general payments, 2019–2025

Across 165 payments — averaging $51.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amarin Pharma, Inc.$1K
  • Johnson & Johnson$1K
  • Novo Nordisk$798
  • Bayer$689
  • Merck$566
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$8,558100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,572 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$4,958
Medicare patients
26
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$36,572
TrulicityDulaglutide26$28,604
FarxigaDapagliflozin Propanediol20$27,085
OzempicSemaglutide17$23,002
Omega-3 Acid Ethyl Esters35$1,860
LantusInsulin Glargine,hum.Rec.Anlog14$1,372
Albuterol Sulfate HfaAlbuterol Sulfate30$1,355
Atorvastatin Calcium118$1,070
Levothyroxine Sodium46$782
Metoprolol Succinate34$584
Metformin Hcl86$563
Lisinopril85$478
Losartan Potassium48$378
Tamsulosin Hcl32$340
Rosuvastatin Calcium33$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$125$36,57224 claims
Lilly USA, LLCTrulicity$264$28,60426 claims
AstraZenecaFarxiga$2,294$27,08520 claims
Novo NordiskOzempic$798$23,00217 claims
Sanofi-aventis U.S. LLCLantus$20$1,37214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →